Stockpolly
Search
Delisting risk
IVVD · NASDAQ · Biotechnology

Invivyd (IVVD)

Develops monoclonal antibodies for serious viral diseases, beginning with COVID-19 prevention.

$0.8596
Pre-market+0.05 (+6.58%)
At close$0.8065(−8.34%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue0002914111213171414
Cost of revenue000011111121
Gross profit0002813101112161213
437746517132272623295559
Research & development26623130581811108103129
131515211314171715192529
General & administrative13151521131417171519029
Other expenses5−10000000000
Operating income−43−77−46−49−62−19−17−15−11−13−43−46
433221101121
Interest income030021100122
Interest expense040000000000
Other non-operating income−51−3−2−2−1−10−1−1−20
Income before tax−39−74−43−47−61−18−16−15−10−11−41−44
Net income from continuing operations−39−74−43−47−61−18−16−15−10−11−41−44
Net income−39−74−43−47−61−18−16−15−10−11−41−44
EPS, basic−$0.36−$0.67−$0.38−$0.40−$0.51−$0.15−$0.14−$0.12−$0.06−$0.06−$0.13−$0.14
EPS, diluted−$0.36−$0.67−$0.38−$0.40−$0.51−$0.15−$0.14−$0.12−$0.06−$0.06−$0.13−$0.14
Weighted average shares, basic110110116119119119120120170172310320
Weighted average shares, diluted110110116119119119120120170172310320
EBITDA−38−77−43−47−60−17−16−14−10−11−41−46
Depreciation & amortization111112110010
EBIT−38−77−43−47−61−18−16−15−10−11−41−46